|
2025-03-04 |
2025-03-03 |
V
Vente
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Dirigeant
|
2 527
-1.7%
18,54
46 841 USD
|
2 527
-1.7%
|
18,54
|
46 841 USD
|
|
|
2025-03-04 |
2025-03-03 |
V
Vente
|
Paravasthu Mukund
Chief Operating Officer
Dirigeant
|
250
-0.8%
18,54
4 634 USD
|
250
-0.8%
|
18,54
|
4 634 USD
|
|
|
2025-03-04 |
2025-03-03 |
V
Vente
|
Weinberg Uri
Chief Innovation Officer
Dirigeant
|
268
-0.2%
18,92
5 071 USD
|
268
-0.2%
|
18,92
|
5 071 USD
|
|
|
2025-03-04 |
2025-03-03 |
V
Vente
|
Cordova Ashley
Chief Executive Officer
Dirigeant
|
2 053
-1.0%
18,54
38 055 USD
|
2 053
-1.0%
|
18,54
|
38 055 USD
|
|
|
2025-03-03 |
2025-02-28 |
V
Vente
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Dirigeant
|
2 770
-1.9%
18,28
50 648 USD
|
2 770
-1.9%
|
18,28
|
50 648 USD
|
|
|
2025-03-03 |
2025-02-28 |
V
Vente
|
Paravasthu Mukund
Chief Operating Officer
Dirigeant
|
368
-1.2%
18,28
6 729 USD
|
368
-1.2%
|
18,28
|
6 729 USD
|
|
|
2025-03-03 |
2025-02-28 |
V
Vente
|
Weinberg Uri
Chief Innovation Officer
Dirigeant
|
311
-0.2%
18,31
5 695 USD
|
311
-0.2%
|
18,31
|
5 695 USD
|
|
|
2025-03-03 |
2025-02-28 |
V
Vente
|
Weinberg Uri
Chief Innovation Officer
Dirigeant
|
4 326
-2.5%
18,78
81 254 USD
|
4 326
-2.5%
|
18,78
|
81 254 USD
|
|
|
2025-03-03 |
2025-02-28 |
V
Vente
|
Cordova Ashley
Chief Executive Officer
Dirigeant
|
2 341
-1.1%
18,28
42 804 USD
|
2 341
-1.1%
|
18,28
|
42 804 USD
|
|
|
2025-03-03 |
2025-02-27 |
V
Vente
|
Leupin Nicolas
Chief Medical Officer
Dirigeant
|
161
-0.3%
20,55
3 308 USD
|
161
-0.3%
|
20,55
|
3 308 USD
|
|
|
2025-03-03 |
2025-02-27 |
V
Vente
|
Leupin Nicolas
Chief Medical Officer
Dirigeant
|
830
-1.6%
19,92
16 535 USD
|
830
-1.6%
|
19,92
|
16 535 USD
|
|
|
2025-03-03 |
2025-02-27 |
V
Vente
|
Puri Michal Nath
Chief Human Resources Officer
Dirigeant
|
225
-0.2%
20,55
4 624 USD
|
225
-0.2%
|
20,55
|
4 624 USD
|
|
|
2025-03-03 |
2025-02-27 |
V
Vente
|
Puri Michal Nath
Chief Human Resources Officer
Dirigeant
|
1 162
-1.1%
19,92
23 149 USD
|
1 162
-1.1%
|
19,92
|
23 149 USD
|
|
|
2025-03-03 |
2025-02-27 |
V
Vente
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Dirigeant
|
1 989
-1.3%
20,55
40 872 USD
|
1 989
-1.3%
|
20,55
|
40 872 USD
|
|
|
2025-03-03 |
2025-02-27 |
V
Vente
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Dirigeant
|
10 277
-6.4%
19,92
204 737 USD
|
10 277
-6.4%
|
19,92
|
204 737 USD
|
|
|
2025-03-03 |
2025-02-27 |
V
Vente
|
Paravasthu Mukund
Chief Operating Officer
Dirigeant
|
267
-0.9%
20,55
5 487 USD
|
267
-0.9%
|
20,55
|
5 487 USD
|
|
|
2025-03-03 |
2025-02-27 |
V
Vente
|
Paravasthu Mukund
Chief Operating Officer
Dirigeant
|
1 379
-4.4%
19,92
27 472 USD
|
1 379
-4.4%
|
19,92
|
27 472 USD
|
|
|
2025-03-03 |
2025-02-27 |
V
Vente
|
Cordova Ashley
Chief Executive Officer
Dirigeant
|
1 808
-0.9%
20,55
37 153 USD
|
1 808
-0.9%
|
20,55
|
37 153 USD
|
|
|
2025-03-03 |
2025-02-27 |
V
Vente
|
Cordova Ashley
Chief Executive Officer
Dirigeant
|
9 345
-4.3%
19,92
186 170 USD
|
9 345
-4.3%
|
19,92
|
186 170 USD
|
|
|
2025-01-15 |
2025-01-11 |
V
Vente
|
Paravasthu Mukund
Chief Operating Officer
Dirigeant
|
2 160
-6.4%
26,81
57 906 USD
|
2 160
-6.4%
|
26,81
|
57 906 USD
|
|
|
2024-11-06 |
2024-11-02 |
V
Vente
|
Paravasthu Mukund
Chief Operating Officer
Dirigeant
|
44
-1.3%
16,69
734 USD
|
44
-1.3%
|
16,69
|
734 USD
|
|
|
2024-11-04 |
2024-11-01 |
V
Vente
|
Paravasthu Mukund
Chief Operating Officer
Dirigeant
|
160
-4.4%
15,88
2 540 USD
|
160
-4.4%
|
15,88
|
2 540 USD
|
|
|
2024-11-04 |
2024-11-01 |
V
Vente
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Dirigeant
|
598
-0.4%
15,94
9 531 USD
|
598
-0.4%
|
15,94
|
9 531 USD
|
|
|
2024-11-04 |
2024-10-31 |
V
Vente
|
Puri Michal Nath
Chief Human Resources Officer
Dirigeant
|
810
-0.7%
15,79
12 792 USD
|
810
-0.7%
|
15,79
|
12 792 USD
|
|
|
2024-08-05 |
2024-08-02 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
688
-0.3%
20,14
13 857 USD
|
688
-0.3%
|
20,14
|
13 857 USD
|
|
|
2024-06-06 |
2024-06-04 |
V
Vente
|
Scannell Timothy J
Administrateur non-exécutif
|
964
-24.5%
23,89
23 027 USD
|
964
-24.5%
|
23,89
|
23 027 USD
|
|
|
2024-06-06 |
2024-06-04 |
V
Vente
|
VERNON W ANTHONY
Administrateur non-exécutif
|
964
-0.6%
23,89
23 033 USD
|
964
-0.6%
|
23,89
|
23 033 USD
|
|
|
2024-06-06 |
2024-06-04 |
V
Vente
|
LEUNG GABRIEL
Administrateur non-exécutif
|
964
-1.2%
23,89
23 025 USD
|
964
-1.2%
|
23,89
|
23 025 USD
|
|
|
2024-03-05 |
2024-03-04 |
V
Vente
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Dirigeant
|
840
-0.5%
16,01
13 448 USD
|
840
-0.5%
|
16,01
|
13 448 USD
|
|
|
2024-03-05 |
2024-03-04 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
1 217
-0.5%
16,01
19 484 USD
|
1 217
-0.5%
|
16,01
|
19 484 USD
|
|
|
2024-03-05 |
2024-03-01 |
V
Vente
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Dirigeant
|
1 679
-1.0%
16,03
26 909 USD
|
1 679
-1.0%
|
16,03
|
26 909 USD
|
|
|
2024-03-05 |
2024-03-01 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
2 107
-0.8%
16,03
33 769 USD
|
2 107
-0.8%
|
16,03
|
33 769 USD
|
|
|
2024-02-29 |
2024-02-28 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
2 303
-0.9%
16,14
37 177 USD
|
2 303
-0.9%
|
16,14
|
37 177 USD
|
|
|
2024-02-29 |
2024-02-28 |
V
Vente
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Dirigeant
|
2 078
-1.3%
16,14
33 545 USD
|
2 078
-1.3%
|
16,14
|
33 545 USD
|
|
|
2023-11-08 |
2023-11-07 |
VP
Vente planifiée
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
382
-0.3%
12,65
4 832 USD
|
382
-0.3%
|
12,65
|
4 832 USD
|
|
|
2023-09-05 |
2023-09-01 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
294
-0.1%
21,82
6 414 USD
|
294
-0.1%
|
21,82
|
6 414 USD
|
|
|
2023-09-05 |
2023-09-01 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
273
-0.2%
21,82
5 956 USD
|
273
-0.2%
|
21,82
|
5 956 USD
|
|
|
2023-09-05 |
2023-09-01 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
883
-0.9%
21,82
19 265 USD
|
883
-0.9%
|
21,82
|
19 265 USD
|
|
|
2023-08-04 |
2023-08-02 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
1 144
-1.1%
30,25
34 607 USD
|
1 144
-1.1%
|
30,25
|
34 607 USD
|
|
|
2023-03-07 |
2023-03-07 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
2 315
-4.1%
75,59
174 999 USD
|
2 315
-4.1%
|
75,59
|
174 999 USD
|
|
|
2023-03-07 |
2023-03-07 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
6 003
-9.6%
75,00
450 206 USD
|
6 003
-9.6%
|
75,00
|
450 206 USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
20 415
-8.9%
76,16
1 554 794 USD
|
20 415
-8.9%
|
76,16
|
1 554 794 USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
1 692
-0.7%
76,16
128 862 USD
|
1 692
-0.7%
|
76,16
|
128 862 USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
3 528
-1.5%
76,16
268 690 USD
|
3 528
-1.5%
|
76,16
|
268 690 USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
16 909
-11.9%
76,16
1 287 779 USD
|
16 909
-11.9%
|
76,16
|
1 287 779 USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
2 942
-2.0%
76,16
224 061 USD
|
2 942
-2.0%
|
76,16
|
224 061 USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
1 570
-1.1%
76,16
119 570 USD
|
1 570
-1.1%
|
76,16
|
119 570 USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Burke William Patrick
Chief Human Resources Officer
Dirigeant
|
593
-0.9%
76,16
45 163 USD
|
593
-0.9%
|
76,16
|
45 163 USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
775
-0.8%
76,16
59 024 USD
|
775
-0.8%
|
76,16
|
59 024 USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
4 730
-4.4%
76,16
360 234 USD
|
4 730
-4.4%
|
76,16
|
360 234 USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
888
-1.4%
76,16
67 630 USD
|
888
-1.4%
|
76,16
|
67 630 USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
4 403
-6.5%
76,16
335 330 USD
|
4 403
-6.5%
|
76,16
|
335 330 USD
|
|
|
2023-03-06 |
2023-03-03 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
2 059
-2.9%
77,64
159 859 USD
|
2 059
-2.9%
|
77,64
|
159 859 USD
|
|
|
2023-03-06 |
2023-03-02 |
V
Vente
|
Burke William Patrick
Chief Human Resources Officer
Dirigeant
|
281
-0.4%
75,28
21 153 USD
|
281
-0.4%
|
75,28
|
21 153 USD
|
|
|
2023-03-06 |
2023-03-02 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
1 213
-0.7%
75,28
91 312 USD
|
1 213
-0.7%
|
75,28
|
91 312 USD
|
|
|
2023-03-06 |
2023-03-02 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
1 055
-1.1%
75,28
79 418 USD
|
1 055
-1.1%
|
75,28
|
79 418 USD
|
|
|
2023-03-06 |
2023-03-02 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
937
-0.9%
75,28
70 535 USD
|
937
-0.9%
|
75,28
|
70 535 USD
|
|
|
2023-03-06 |
2023-03-02 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
844
-1.4%
75,28
63 535 USD
|
844
-1.4%
|
75,28
|
63 535 USD
|
|
|
2023-03-03 |
2023-03-02 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
308
-0.5%
76,05
23 424 USD
|
308
-0.5%
|
76,05
|
23 424 USD
|
|
|
2023-03-03 |
2023-03-02 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
3 799
-6.0%
75,32
286 154 USD
|
3 799
-6.0%
|
75,32
|
286 154 USD
|
|
|
2023-03-02 |
2023-03-01 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
2 164
-1.2%
76,36
165 248 USD
|
2 164
-1.2%
|
76,36
|
165 248 USD
|
|
|
2023-03-02 |
2023-03-01 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
1 684
-2.6%
76,36
128 594 USD
|
1 684
-2.6%
|
76,36
|
128 594 USD
|
|
|
2023-03-02 |
2023-03-01 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
1 923
-1.9%
76,36
146 845 USD
|
1 923
-1.9%
|
76,36
|
146 845 USD
|
|
|
2023-03-02 |
2023-03-01 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
2 198
-2.2%
76,36
167 845 USD
|
2 198
-2.2%
|
76,36
|
167 845 USD
|
|
|
2023-03-02 |
2023-03-01 |
V
Vente
|
Burke William Patrick
Chief Human Resources Officer
Dirigeant
|
755
-1.1%
76,36
57 654 USD
|
755
-1.1%
|
76,36
|
57 654 USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
7 183
-13.5%
120,00
861 960 USD
|
7 183
-13.5%
|
120,00
|
861 960 USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
7 183
-13.5%
114,00
818 863 USD
|
7 183
-13.5%
|
114,00
|
818 863 USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
5 517
-10.7%
108,00
595 836 USD
|
5 517
-10.7%
|
108,00
|
595 836 USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
7 500
-14.0%
108,00
810 000 USD
|
7 500
-14.0%
|
108,00
|
810 000 USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
7 826
-14.5%
108,00
845 208 USD
|
7 826
-14.5%
|
108,00
|
845 208 USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
1 010
-2.1%
117,00
118 170 USD
|
1 010
-2.1%
|
117,00
|
118 170 USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
526
-1.1%
115,03
60 508 USD
|
526
-1.1%
|
115,03
|
60 508 USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
417
-0.9%
108,00
45 036 USD
|
417
-0.9%
|
108,00
|
45 036 USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
2 345
-4.6%
119,01
279 073 USD
|
2 345
-4.6%
|
119,01
|
279 073 USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Weinberg Uri
Chief Science Officer
Dirigeant
|
1 201
-2.7%
120,00
144 120 USD
|
1 201
-2.7%
|
120,00
|
144 120 USD
|
|
